Association Between the Early Discontinuation of Durvalumab and Poor Survival in Patients With Stage III NSCLC
{{output}}
Introduction: Durvalumab after concurrent chemoradiation (cCRT) has been found to improve outcomes of patients with unresected stage III NSCLC. However, the survival impact of discontinuing durvalumab early owing to adverse event... ...
